VC004
VC004 is an experimental small-molecule drug from Jiangsu vcare pharmaceutical technology co. in phase 3 trials, with its target not yet stated publicly.
Overview
VC004 is a small-molecule drug developed by Jiangsu vcare pharmaceutical technology co.. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06658353 (Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumours). The largest, NCT06658353, plans to enrol 54 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"VC004" OR ABSTRACT:"VC004") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VC004, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentA166
Shares the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares the tags pipeline, ctgov-ingest.
- TreatmentABBV-706
Shares the tags pipeline, ctgov-ingest.
- TreatmentAbexinostat
Shares the tags pipeline, ctgov-ingest.
- TreatmentABSK061
Shares the tags pipeline, ctgov-ingest.
- TreatmentABT-301
Shares the tags pipeline, ctgov-ingest.
- TreatmentAcasunlimab
Shares the tags pipeline, ctgov-ingest.
- TreatmentADG126
Shares the tags pipeline, ctgov-ingest.